BioVision 8/13

Neuropoietin, murine recombinant

CATALOG #: 7180-10 10 μg

7180-50 50 μg

ALTERNATE NAMES: NPO, NP

SOURCE: E. Coli

PURITY: ≥ 98% by SDS-PAGE gel and HPLC analyses

MOL. WEIGHT: 19.8 kDa

ENDOTOXIN LEVEL: $< 0.1 \text{ ng/}\mu\text{g} \text{ of protein } (<1\text{EU/}\mu\text{g}).$

FORM: Lyophilized

FORMULATION: Sterile filtered through a 0.2 micron filter.

Lyophilized from 2.5 mM Tris, pH 10.2 and 0.5

mM DTT

STORAGE CONDITIONS: Store at -20°C. After reconstitution, aliquot and

store at -20°C to -80°C. Avoid repeated freezing

and thawing cycles.

RECONSTITUTION:

Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.

DESCRIPTION:

Neuropoietin is a newly identified member of the IL-6 cytokine family. Members of this family, including IL-6, IL-11, oncostatin M, leukemia inhibitory factor (LIF), cardiotrophin-1 (CT-1), cardiotrophin-like cytokine, and CNTF, display a four-helix bundle structure, and signal through gp130-containing receptor complexes. Neuropoietin, which is predominantly expressed in neuroepithelia during embryonic life, acts through a receptor complex comprising CNTF receptor-α component, gp130, and LIF receptor. Like CNTF, it promotes the survival of embryonic motor neurons and could increase the proliferation of neural precursor cells in the presence of EGF and FGF-2. Interestingly, the human Neuropoietin gene has evolved toward a pseudogene, suggesting that the alternative signaling via CNTF is an effective compensatory pathway. Recombinant murine

AMINO ACID SEQUENCE:

MAPISPSEPI GQAYSLALYM QKNTSALLQT YLQHQGSPFS DPGFSAPELQ LSTLPSAAVS FKTWHAMEDA ERLSRAQGAF LALTQHLQLV GDDQSYLNPG SPILLAQLGA ARLRAQGLLG NMAAIMTALG LPIPPEEDTL GFVPFGASAF ERKCRGYIVT REYGHWTDRA VRDLALLKAK YSA

For research use only

BIOLOGICAL ACTIVITY:

Determined by the dose dependent stimulation of the proliferation of human TF-1 cells. The expected ED $_{50}$ is 0.5-0.8 μ g/ml.

RELATED PRODUCTS:

- IL-6, human recombinant (Cat # 4143-20, -50, -1000)
- IL-6, murine recombinant (Cat # 4144-10, -50, -1000)
- IL-6, rat recombinant (Cat # 4145-10, -100, -1000)
- IL-6 Antibody (Cat # 5143-200)
- IL-6 Antibody (Cat # 5144-200)
- IL-6 Antibody (Cat # 5145-200)

FOR RESEARCH USE ONLY! Not to be used in humans.

